FR2845912A1 - Cosmetic method for developing the bust and improving the figure, comprises separate lipolytic and lipogenic components - Google Patents
Cosmetic method for developing the bust and improving the figure, comprises separate lipolytic and lipogenic components Download PDFInfo
- Publication number
- FR2845912A1 FR2845912A1 FR0212999A FR0212999A FR2845912A1 FR 2845912 A1 FR2845912 A1 FR 2845912A1 FR 0212999 A FR0212999 A FR 0212999A FR 0212999 A FR0212999 A FR 0212999A FR 2845912 A1 FR2845912 A1 FR 2845912A1
- Authority
- FR
- France
- Prior art keywords
- sep
- extract
- product
- lipolytic
- bust
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 21
- 230000002366 lipolytic effect Effects 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 12
- 230000003520 lipogenic effect Effects 0.000 title claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 28
- 210000000481 breast Anatomy 0.000 claims description 19
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 10
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 8
- 229960005305 adenosine Drugs 0.000 claims description 8
- 229960001948 caffeine Drugs 0.000 claims description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 6
- 230000000940 lipogenetic effect Effects 0.000 claims description 6
- 240000008669 Hedera helix Species 0.000 claims description 5
- 210000001789 adipocyte Anatomy 0.000 claims description 5
- 239000000419 plant extract Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 241001474374 Blennius Species 0.000 claims description 3
- 240000001432 Calendula officinalis Species 0.000 claims description 3
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 3
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 240000000353 Ruscus aculeatus Species 0.000 claims description 3
- 235000003500 Ruscus aculeatus Nutrition 0.000 claims description 3
- 240000007164 Salvia officinalis Species 0.000 claims description 3
- 235000002912 Salvia officinalis Nutrition 0.000 claims description 3
- 241000894477 Ulva compressa Species 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- -1 cola extract Chemical compound 0.000 claims description 3
- 235000002020 sage Nutrition 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims description 2
- 241000086254 Arnica montana Species 0.000 claims description 2
- 235000002992 Betula pubescens Nutrition 0.000 claims description 2
- 241001520764 Betula pubescens Species 0.000 claims description 2
- 244000308505 Filipendula ulmaria Species 0.000 claims description 2
- 235000016622 Filipendula ulmaria Nutrition 0.000 claims description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 2
- 244000141009 Hypericum perforatum Species 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 229960004203 carnitine Drugs 0.000 claims description 2
- 229940098366 cola extract Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 235000008434 ginseng Nutrition 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000000399 hydroalcoholic extract Substances 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 230000002608 insulinlike Effects 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 108091006082 receptor inhibitors Proteins 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 235000015639 rosmarinus officinalis Nutrition 0.000 claims description 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 claims description 2
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 241001530490 Salvia rosmarinus Species 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000002803 maceration Methods 0.000 description 12
- 239000003925 fat Substances 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 230000002035 prolonged effect Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229960000541 cetyl alcohol Drugs 0.000 description 5
- 235000020710 ginseng extract Nutrition 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- VYGQUTWHTHXGQB-FFHKNEKCSA-N retinyl palmitate Natural products CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 235000019493 Macadamia oil Nutrition 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 229940086555 cyclomethicone Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000010469 macadamia oil Substances 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 4
- 229940108325 retinyl palmitate Drugs 0.000 description 4
- 235000019172 retinyl palmitate Nutrition 0.000 description 4
- 239000011769 retinyl palmitate Substances 0.000 description 4
- 229940099259 vaseline Drugs 0.000 description 4
- 239000009429 Ginkgo biloba extract Substances 0.000 description 3
- 241000208341 Hedera Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229940075510 carbopol 981 Drugs 0.000 description 3
- 230000009194 climbing Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940068052 ginkgo biloba extract Drugs 0.000 description 3
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- 244000018844 Cornus canadensis Species 0.000 description 2
- 235000003362 Cornus canadensis Nutrition 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229940096529 carboxypolymethylene Drugs 0.000 description 2
- 230000036232 cellulite Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940031766 diethanolamine cetyl phosphate Drugs 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229940057874 phenyl trimethicone Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229940112950 sage extract Drugs 0.000 description 2
- 235000020752 sage extract Nutrition 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000208983 Arnica Species 0.000 description 1
- 241001026287 Chrysanthellum indicum Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 241001184198 Orthosiphon Species 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 235000020759 St. John’s wort extract Nutrition 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940089116 arnica extract Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 201000010759 hypertrophy of breast Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940099416 st. john's wort extract Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
Abstract
Description
<Desc/Clms Page number 1> <Desc / Clms Page number 1>
Composition cosmétique binaire pour le développement du buste féminin et l'amélioration de la silhouette. Binary cosmetic composition for the development of the female bust and the improvement of the silhouette.
L'invention a pour objet une composition cosmétique binaire ou complexe cosmétique constitué de deux produits dont l'utilisation conjointe a pour effet de développer les seins. The invention relates to a binary cosmetic composition or cosmetic complex consisting of two products whose joint use has the effect of developing the breasts.
L'invention se rapporte également à un procédé de traitement cosmétique du corps pour améliorer la silhouette. The invention also relates to a method of cosmetic treatment of the body to improve the silhouette.
L'usage de dérivé animal ou végétal pour provoquer une tension de la peau du buste est connu (FR 2 296 425). L'amélioration apportée est cependant fugace et plutôt mécanique ou indirecte par des effets astringents ou de stimulation de la circulation sanguine locale. The use of animal or plant derived to cause a tension of the skin of the bust is known (FR 2,296,425). The improvement is however fleeting and rather mechanical or indirect by astringent effects or stimulation of the local blood circulation.
L'usage d'hormones oestrogèniques ou de phytooestrogènes peut être envisagé mais présente un risque potentiel et est interdit en cosmétique dans certains pays (liste des substances dont l'emploi dans les produits cosmétiques et les produits d'hygiène corporelle est soumis à interdiction de l'annexe Il de la Directive cosmétique 76/768/CEE modifiée : oestrogène et substances à effet). The use of estrogen hormones or phytoestrogens may be considered but presents a potential risk and is prohibited in cosmetics in some countries (list of substances whose use in cosmetics and personal hygiene products is subject to a ban on Annex II of the amended Cosmetic Directive 76/768 / EEC: estrogen and substances with effect).
Des composés organiques différents ont été décrits (EP-0281647) mais agissent plutôt comme des prothèses. Different organic compounds have been described (EP-0281647) but rather act as prostheses.
Des promoteurs de synthèse de graisse ont été proposés (JP-11199499) pour permettre l'augmentation mammaire. Cette solution meilleure que les précédentes a cependant l'inconvénient d'augmenter la masse de graisse totale de la personne qui l'utilise ce qui n'est pas en général recherché. L'efficacité est également faible et est réduite à la capacité du tissu mammaire à synthétiser cette graisse. Fat synthesis promoters have been proposed (JP-11199499) to allow breast augmentation. This better solution than the previous ones, however, has the disadvantage of increasing the total mass of fat of the person who uses it which is not generally sought. Efficacy is also low and is reduced to the ability of breast tissue to synthesize this fat.
Des recherches et expérimentations conduites par l'auteur de la présente invention ont permis de constater que l'application, sur les hanches ou autres zones adipeuses de la partie inférieure du tronc ou du corps, d'un produit Researches and experiments conducted by the author of the present invention have found that the application, on the hips or other fat areas of the lower part of the trunk or the body, of a product
<Desc/Clms Page number 2><Desc / Clms Page number 2>
cosmétique ayant pour effet de stimuler localement la lipolyse, associée à l'application sur le buste d'un second produit cosmétique ayant pour effet de capter et de fixer les graisses ainsi libérées, permettait d'obtenir un développement notable des seins sans risque d'effet secondaire. De plus, le volume disgracieux des hanches du sujet se trouve réduit de ce que la poitrine a gagné, ce qui est un avantage supplémentaire pour la silhouette. cosmetic effect having the effect of locally stimulating lipolysis, associated with the application on the bust of a second cosmetic product having the effect of capturing and fixing the fat thus released, allowed to obtain a significant development of the breasts without risk of side effect. In addition, the unsightly volume of the subject's hips is reduced by the fact that the chest has gained, which is an added advantage for the figure.
La présente invention se rapporte à une composition cosmétique binaire pour le développement du buste, constituée d'une part, d'un produit doté de propriétés lipolytiques destiné à être appliqué sur une zone adipeuse du corps, et d'autre part, d'un produit doté de propriétés lipogénétiques ou d'une capacité à capter les graisses et à les fixer, destiné à être appliqué sur la ou les parties du buste que l'on désire développer. The present invention relates to a binary cosmetic composition for the development of the bust, consisting, on the one hand, of a product having lipolytic properties intended to be applied to an adipose zone of the body, and on the other hand, of a product with lipogenic properties or ability to capture fat and fix them, intended to be applied to the part or parts of the bust that is desired to develop.
Le complexe cosmétique selon l'invention provoque, d'une part, une lipolyse des graisses contenues dans les adipocytes des tissus, de préférence ceux des hanches (dont la présence est généralement abondante à ce niveau chez les femmes, et jugée disgracieuse), et, d'autre part, un captage et une fixation des graisses ainsi libérées, de préférence au niveau des seins pour en augmenter le volume. The cosmetic complex according to the invention causes, on the one hand, a lipolysis of the fats contained in the adipocytes of the tissues, preferably those of the hips (the presence of which is generally abundant at this level in women, and considered unsightly), and on the other hand, capture and fixation of the fats thus released, preferably at the level of the breasts to increase the volume.
Le produit présentant des propriétés lipolytiques contient de façon préférentielle quoique nullement limitative, des xanthines, et notamment la caféine ou encore le nicotinate d'alpha-tocophérol, l'extrait de cola, la carnitine, la vitamine E et son acétate, des bloqueurs de récepteur alpha 2 comme le Ginkgo biloba, des inhibiteurs des récepteurs NPY comme l'extrait de Enteromorpha compressa ainsi que tout autre agent lipolytique capable de libérer les graisses des adipocytes. The product having lipolytic properties preferably contains, although by no means limiting, xanthines, and in particular caffeine or else alpha-tocopherol nicotinate, cola extract, carnitine, vitamin E and its acetate, blockers of alpha 2 receptor such as Ginkgo biloba, NPY receptor inhibitors such as Enteromorpha compressa extract and any other lipolytic agent capable of releasing fat from adipocytes.
Pour ces agents lipolytiques, on peut citer : les extraits végétaux huileux dont : # L'extrait de lierre grimpant (Hedera hélix), par exemple obtenu par For these lipolytic agents, mention may be made of: oily plant extracts, of which: # The climbing ivy extract (Hedera helix), for example obtained by
<Desc/Clms Page number 3><Desc / Clms Page number 3>
macération prolongée des feuilles dans du propylène glycol ; # L'extrait d'arnica (Arnica montana L), par exemple obtenu par macération des capitules floraux d'arnica dans du glycol ou dans de l'huile de noyaux d'abricot ; # L'extrait de romarin (Rosmarinus officinalis N), par exemple obtenu par macération prolongée des feuilles dans du glycol ou de l'huile de noyaux d'abricot ; # L'extrait de souci (Calendule officinalis), par exemple obtenu par macération prolongée des fleurs dans du glycol ou de l'huile de noyaux d'abricot ; # L'extrait de sauge (Salvia officinalis L), par exemple obtenu par macération prolongée des feuilles dans du glycol ou de l'huile de noyaux d'abricot ; # L'extrait de millepertuis (Hypericum perforatum), par exemple obtenu à partir des fleurs par macération dans une huile neutre ou dans glycol; # L'extrait de fragon par exemple obtenu à partir de rhizomes de fragon (Ruscus aculeatus L), préalablement broyés et extraits à l'aide d'une solution hydroalcoolique d'un alcool ayant de 3 à 6 atomes de carbone de préférence à l'aide de n-butanol saturé d'eau ; # L'extrait d'ulmaire (Filipendula ulmaria L), par exemple obtenu par macération prolongée de la plante entière dans une huile neutre ou dans du myristate d'isopropyle; # L'extrait d'orthosiphon (Ortosifon stamincus benth), par exemple obtenu par macération prolongée des capitules floraux dans une huile neutre ; # L'extrait d'algues par exemple obtenu par macération prolongée de la plante entière dans une huile oxyéthylénée les extraits végétaux hydrosolubles dont : prolonged maceration of the leaves in propylene glycol; Arnica extract (Arnica montana L), for example obtained by maceration of the flower heads of arnica in glycol or in apricot kernel oil; # Rosemary extract (Rosmarinus officinalis N), for example obtained by prolonged maceration of the leaves in glycol or apricot kernel oil; # Marigold extract (Calendula officinalis), for example obtained by prolonged maceration of flowers in glycol or apricot kernel oil; # Sage extract (Salvia officinalis L), for example obtained by prolonged maceration of the leaves in glycol or apricot kernel oil; # St. John's wort extract (Hypericum perforatum), for example obtained from flowers by maceration in a neutral oil or in glycol; # The birch extract obtained, for example, from bunchberry rhizomes (Ruscus aculeatus L), previously ground and extracted with the aid of a hydroalcoholic solution of an alcohol having from 3 to 6 carbon atoms, preferably using water-saturated n-butanol; # The Ulmaria extract (Filipendula ulmaria L), for example obtained by prolonged maceration of the whole plant in a neutral oil or in isopropyl myristate; # Orthosiphon extract (Ortosifon stamincus benth), for example obtained by prolonged maceration of flower heads in a neutral oil; # Algae extract, for example, obtained by prolonged maceration of the whole plant in an oxyethylenated oil, the water-soluble plant extracts of which:
<Desc/Clms Page number 4><Desc / Clms Page number 4>
# L'extrait hydrosoluble d'algues, extrait hydroglycolique obtenu, par exemple, par macération prolongée de thalles dans une solution d'extrait hydroglycolique; # L'extrait hydrosoluble de lierre grimpant (Hedera hélix) obtenu, par exemple, par macération prolongée de feuilles et de tiges dans une solution d'extrait hydroglycolique; # L'extrait hydrosoluble de bouleau (Betula alba) obtenu, par exemple, par macération prolongée d'écorce dans une solution d'extrait hydroglycolique; les extraits végétaux hydro-alcooliques dont l'extrait hydroalcoolique de noix de cola (Cola Nipida), par exemple obtenu par lixiviation de graines à l'alcool ;
Le produit destiné à capter et fixer les graisses libérées après lipolyse, ou produit "lipogénétique" contient de façon préférentielle quoique nullement limitative de l'adénosine et/ou de la vitamine A et/ou du Pro-rétinol et/ou du Ginseng comme toute autre substance capable de retenir les graisses dans les adipocytes mammaires parmi lesquelles on peut citer les substances insuline-like ou tout facteur de type IGF (insuline growth factor). # The water-soluble extract of algae, hydroglycolic extract obtained, for example, by prolonged maceration of thalli in a solution of hydroglycolic extract; # The water-soluble extract of climbing ivy (Hedera helix) obtained, for example, by prolonged maceration of leaves and stems in a solution of hydroglycolic extract; # The water-soluble extract of birch (Betula alba) obtained, for example, by prolonged maceration of bark in a solution of hydroglycolic extract; hydroalcoholic plant extracts including hydroalcoholic extract of cola nuts (Cola Nipida), for example obtained by leaching seeds with alcohol;
The product intended to capture and fix the fats released after lipolysis, or "lipogenetic" product preferentially contains, although in no way limiting, adenosine and / or vitamin A and / or Pro-retinol and / or Ginseng as any another substance capable of retaining fat in mammary adipocytes, among which mention may be made of insulin-like substances or any type of IGF (insulin growth factor) type factor.
Le complexe cosmétique selon l'invention peut se présenter sous différentes formes, en particulier sous la forme d'une émulsion huile dans eau (H/E) ou eau dans huile (E/H) ayant l'aspect d'une crème ou d'un lait ou sous forme d'un gel et également sous forme de vésicules lipidiques constituées de lipides ioniques (liposomes) ou de lipides non ioniques. The cosmetic complex according to the invention may be in various forms, in particular in the form of an oil-in-water (O / W) or water-in-oil (W / O) emulsion having the appearance of a cream or a milk or in the form of a gel and also in the form of lipid vesicles consisting of ionic lipids (liposomes) or nonionic lipids.
La présente invention peut également être utilisée avantageusement pour solutionner le problème des poitrines disproportionnées (un des seins plus volumineux que l'autre). Dans ce cas le produit lipolytique sera appliqué sur le sein le plus gros et / ou sur les hanches et l'autre produit sur le sein le plus petit. The present invention can also be used advantageously to solve the problem of disproportionate breasts (one of the breasts larger than the other). In this case, the lipolytic product will be applied to the larger breast and / or the hips and the other product to the smaller breast.
<Desc/Clms Page number 5><Desc / Clms Page number 5>
Selon un premier mode de réalisation de l'invention, le produit lipogénétique est composé de : - Acrylate C10-30 0,50 g - Adénosine.................................................................................... 0,01 g - Ethoxydiglycol............................................................................ 5,00 g - Extrait de ginseng ........................................................................ 0,20 g - Alcool.......................................................................................... 2,00 g - Rétinyl palmitate ......................................................................... 0,01 g - Carbomère ................................................................................... 0.126 g - Butylène glycol............................................................................ 0,24 g - EDTA .......................................................................................... 0.005 g - Conservateur ............................................................................... 0.867 g - Huile de macadamia .................................................................... 0. 5 g - Lécithine hydrogénée 0. 09 g - Cyclométhicone........................................................................... 0,20 g - TEA 99% ..................................................................................... 0,62 g - Extrait de soja .............................................................................. 5,00 g - Colorants.....................................................................................0,0002 g - Eau déminéralisée qsp ................................................................ 100 g Selon un second mode de réalisation, ce produit est composé de : - Carboxypolyméthylène ou bien Polymère carboxylique............. 0. 40 g - Diéthanolamine cétyl phosphate.................................................. 1.50 g - Octyl dodecanol........................................................................... 5.50 g - Alcool cétylique........................................................................... 1 g - Huile minérale ............................................................................. 2.00 g - Acide stéarique ............................................................................ 1 g - Alcool stérylique éthoxylé (20E)................................................. 0.30 g According to a first embodiment of the invention, the lipogenetic product is composed of: Acrylate C10-30 0.50 g Adenosine ..................... .................................................. ............. 0.01 g - Ethoxydiglycol ............................... ............................................. 5.00 g - Ginseng extract ............................................... ......................... 0.20 g - Alcohol ................... .................................................. ..................... 2.00 g - Retinyl palmitate ...................... .................................................. 0.01 g - Carbomer ........................................... ........................................ 0.126 g - Butylene glycol ..... .................................................. ..................... 0.24 g - EDTA ....................... .................................................. ................. 0.005 g - Conservative ............................. ...... ............................................ 0.867 g - Macadamia oil .................................................. .................. 0. 5 g - Hydrogenated lecithin 0.9 g - Cyclomethicone ................... .................................................. ...... 0.20 g - TEA 99% .................................... ................................................. 0 , 62 g - Soy extract ........................................... ................................... 5,00 g - Colorants ......... .................................................. .......................... 0.0002 g - Demineralised water qs ................ ................................................ 100 g According to a second embodiment, this product is composed of: - Carboxypolymethylene or carboxylic polymer ............. 0. 40 g - Diethanolamine cetyl phosphate .......... .......................................... 1.50 g - Octyl dodecanol ..... ................................................ ...................... 5.50 g - Cetyl alcohol ....................... .................................................. .. 1 g - Mineral oil ........................................... .................................. 2.00 g - Stearic acid ........... .................................................. ............... 1 g - Ethoxylated Steryl Alcohol (20E) .......................... ....................... 0.30 g
<Desc/Clms Page number 6> <Desc / Clms Page number 6>
Alcool céto-stéarylique................................................................ 1. 80 g
Conservateur ............................................................................... 0. 15 g
Huile de macadamia .................................................................... 0. 50 g
Triéthanolamine........................................................................... 0. 60 g
Cyclométhicone........................................................................... 12 g
Diméthicone copolyol ................................................................. 3. 00 g
Phenyl Triméthicone 2. 00 g
Glycine soja................................................................................. 5. 00 g Sépigel 305 .................................................................................. 1. 00 g
Adénosine .................................................................................... 0. 20 g
Butylène glycol............................................................................ 6. 00 g
Mica et dioxyde de titane 1. 00 g
Extrait de Ginseng (Ginseng panax) ........................................... 0. 20 g
Extrait de lierre grimpant (Hedera hélix).................................... 1 g
Eau déminéralisée qsp ................................................................ 100 g Trois autres exemples de réalisation sont également exposés ci-après : 9/ Emulsion H/E: - Paraffine liquide .......................................................................... 6 g - Lanoline liquide........................................................................... 3 g - Arlacel 165 (commercialisé par Atlas)........................................ 6 g - Tween 60 (commercialisé par Atlas)........................................... 2 g - Alcool cétylique........................................................................... 1. 2 g - Acide stéarique ............................................................................ 2. 5 g - Rétinyl palmitate ......................................................................... 0. 5 g - Huile de silicone volatile............................................................. 10 g - Triéthanolamine........................................................................... 0. 1 g - Conservateur ............................................................................... 0. 3 g - Antioxydants ............................................................................... 0. 3 g - Adénosine.................................................................................... 0. 3 g Ketostearyl alcohol .............................................. .................. 1. 80 g
Curator ................................................. .............................. 0. 15 g
Macadamia oil ............................................... ..................... 0. 50 g
Triethanolamine ................................................. .......................... 0. 60 g
Cyclomethicone ................................................. .......................... 12 g
Dimethicone copolyol ................................................ ................. 3. 00 g
Phenyl Trimethicone 2.00 g
Glycine soy ................................................ ................................. 5. 00 g Sepigel 305 ........... .................................................. ..................... 1. 00 g
Adenosine ................................................. ................................... 0. 20 g
Butylene glycol ................................................ ............................ 6. 00 g
Mica and titanium dioxide 1.00 g
Ginseng extract (Ginseng panax) ........................................... 0. 20 g
Climbing ivy extract (Hedera helix) .................................... 1 g
Demineralized water qs ............................................... ................. 100 g Three other examples of embodiments are also set out below: 9 / O / W emulsion: - liquid paraffin ......... .................................................. ............... 6 g - Liquid lanolin .............................. ............................................. 3 g - Arlacel 165 (marketed by Atlas) ........................................ 6 g - Tween 60 (marketed by Atlas) ........................................... 2 g - Cetyl alcohol ............................................... ............................ 1. 2 g - Stearic acid ............... .................................................. ........... 2. 5 g - Retinyl palmitate ................................ ......................................... 0. 5 g - Volatile silicone oil .................................................. ........... 10 g - Triethanolamine ......................... .................................................. 0. 1g - Conservative ............................................ ................................... 0. 3 g - Antioxidants ......... .................................................. .................... 0. 3 g - Adenosine ........................ .................................................. .......... 0. 3 g
<Desc/Clms Page number 7> <Desc / Clms Page number 7>
Extrait de Gingeng....................................................................... 5 g
Extrait de Sauge (Salvia officinalis L) ........................................ 1 g
Eau déminéralisée qsp ................................................................ 100 g 2/ Crème aux liposomes : - Huile de tournesol ....................................................................... 35 g - Alcool cétylique .......................................................................... 4 g - B-sitostérol.................................................................................. 4 g - Dicétyl phosphate ........................................................................ 0.5 g - Conservateur ............................................................................... 0.3 g - Carbopol 981 (commercialisé par Goodrich) .............................. 0. 2 g - Triéthanolamine........................................................................... 0.2 g
- Sphingosine .................................................................................0.05 g - Adénosine.................................................................................... g - Extrait de Ginseng ....................................................................... 0.5 g - Glycine de fragon (Ruscus aculeatus) ......................................... 1 g - Eau déminéralisée qsp ................................................................ 100 g Les modes de réalisation ci-dessus peuvent avantageusement être utilisés sur les seins afin d'en augmenter le volume. Le mode de réalisation ci-après peut être appliqué sur toutes zones dont le volume doit être augmenté :
Emulsion E/H: - Protégin (commercialisépar Goldschmidt) .................................. 19 g - Glycérine ..................................................................................... g - Huile de vaseline ........................................................................ g - Sulfate de Mg .............................................................................. 0.5 g
- Adénosine....................................................................................0.5 g - Extrait de Ginseng ....................................................................... g - Extrait d'orthosifon (Ortosifon stamincus) ................................. 1 g Gingeng extract ............................................... ........................ 5 g
Sage extract (Salvia officinalis L) ....................................... 1 g
Demineralized water qs ............................................... ................. 100 g 2 / Liposome cream: - Sunflower oil ..................... .................................................. 35 g - Cetyl alcohol ............................................. ............................. 4 g - B-sitosterol ............... .................................................. ................. 4 g - Diketyl phosphate ............................ ............................................ 0.5 g - Conservative .. .................................................. ........................... 0.3 g - Carbopol 981 (marketed by Goodrich) ............. ................. 0. 2 g - Triethanolamine ........................... ................................................ 0.2 g
- Sphingosine ................................................ ................................. 0.05 g - Adenosine ............. .................................................. ..................... g - Ginseng extract ........................ ............................................... 0.5 g - Bunchberry Glycine (Ruscus aculeatus) ......................................... 1 g - Demineralized water qsp .............................................. .................. 100 g The above embodiments can advantageously be used on the breasts to increase the volume. The following embodiment can be applied to all areas whose volume needs to be increased:
W / O emulsion: - Protégin (marketed by Goldschmidt) .................................. 19 g - Glycerin. .................................................. .................................. g - Vaseline oil ........... .................................................. ........... g - Mg Sulfate .................................. ............................................... 0.5 g
- Adenosine ................................................ .................................... 0.5 g - Ginseng extract ........ .................................................. ............. g - Orthosifon extract (Ortosifon stamincus) ........................... ...... 1 g
<Desc/Clms Page number 8> <Desc / Clms Page number 8>
Rétinyl palmitate .........................................................................0.02 g
Conservateur ............................................................................... 0. 2 g
Eau déminéralisée qsp ................................................................ 100 g
Selon l'invention, un mode de réalisation du produit à propriété lipolytique contient : - Acrylate C10-30 .......................................................................... 0,50 g - Carboxyméthyl de méthylsilanol................................................. 8,00 g - Ethoxydiglycol............................................................................ 5,00 g - Acide salicylique .........................................................................0,444 g - Caféine......................................................................................... 2,20 g - Extrait d'Entéromorphia compressa............................................ 1,00 g - Carbomère ................................................................................... 0.126 g - Butylène glycol............................................................................ 0,24 g - EDTA .......................................................................................... 0.005 g - Conservateur ............................................................................... 0.30 g - Huile de macadamia .................................................................... 0.5 g - Lécithine hydrogénée .................................................................. 0.09 g - Cyclométhicone........................................................................... 0,20 g - TEA 99% ..................................................................................... 1,12 g
Extrait de Ginkgobiloba............................................................. 0,75 g - Extrait de Ginkgo biloba .................................................................. 0,75 g
Extrait de Chrysanthellum indicum............................................. 0,05 g
- Colorants .....................................................................................0,0001 g - Eau déminéralisée qsp ................................................................ 100 g Nous citons ci-après d'autres exemples de réalisation du produit lipolytique : Retinyl palmitate ................................................ ......................... 0.02 g
Curator ................................................. .............................. 0. 2 g
Demineralized water qs ............................................... ................. 100 g
According to the invention, an embodiment of the lipolytically active product contains: Acrylate C10-30 ............................. ............................................. 0.50 g - Methylsilanol carboxymethyl ............................................... .. 8.00 g - Ethoxydiglycol .......................................... .................................. 5.00 g - Salicylic acid ......... .................................................. .............. 0.444 g - Caffeine ................................ .................................................. ....... 2.20 g - Entomorphia compressa extract ................................. .................. 1.00 g - Carbomer ................................. .................................................. 0.126 g - Butylene glycol ............................................. ............................... 0.24 g - EDTA ............. .................................................. ........................... 0.005 g - Consist vateur ................................................. .............................. 0.30 g - Macadamia oil .............. .................................................. .... 0.5 g - Hydrogenated lecithin ......................................... ......................... 0.09 g - Cyclomethicone ..................... .................................................. .... 0.20 g - TEA 99% ...................................... ................................................ 1,12 g
Ginkgobiloba extract ............................................... .............. 0,75 g - Ginkgo biloba extract ........................... ....................................... 0,75 g
Chrysanthellum indicum extract ............................................. 0 , 05 g
- Colorants ................................................ ..................................... 0.0001 g - Demineralized water qsp ..... .................................................. ......... 100 g The following are examples of other embodiments of the lipolytic product:
<Desc/Clms Page number 9><Desc / Clms Page number 9>
Exemple 1 : - Carboxypolyméthylène................................................................ 0. 40 g - Diéthanolamine cétyl phosphate.................................................. 1.50 g - Octyl dodecanol........................................................................... 5.50 g - Alcool cétylique ........................................................................... 1.00 g - Huile minérale ............................................................................. 3.00 g - Acide stéarique ............................................................................ 1.00 g - Alcool stérylique éthoxylé (20E)................................................. 0.30 g - Alcool céto-stéarylique................................................................ 1.50 g - Conservateur ............................................................................... 0.30 g - Huile de macadamia .................................................................... 1.00 g - Triéthanolamine........................................................................... 0.60 g - Cyclométhicone........................................................................... 13.0 g - Diméthicone copolyol ................................................................. 1.00 g - Phenyl Triméthicone ................................................................... 2.00 g - Extrait de Ginkgo biloba ............................................................. 0.75 g - Extrait d'algue............................................................................. 1.00 g - Caféine......................................................................................... 2.00 g - Méthylsilanol carboxyméthyl théophylline alginate.................... 8. 00 g - Eau déminéralisée qsp ................................................................ 100 g Exemple 2 : Emulsion gel H/E : - Carbopol 981 (commercialisé par Goodrich) .............................. 0.6 g - Alcool éthylique .......................................................................... 15 g - Huile de silicone volatile............................................................. 3 g
- Huile de purcellin ........................................................................ 7 g - Conservateur................................................................................ 0.3 g
- Caféine anhydre........................................................................... 1 g Example 1: Carboxypolymethylene ............................................. ................... 0. 40 g - Diethanolamine cetyl phosphate ....................... ........................... 1.50 g - Octyl dodecanol .................. .................................................. ....... 5.50 g - Cetyl alcohol ...................................... ..................................... 1.00 g - Mineral oil ........ .................................................. ................... 3.00 g - Stearic acid .......................... .................................................. 1.00 g - Ethoxylated Steryl Alcohol (20E) ......................................... 0.30 g - Ketostearyl alcohol ................................... ............................. 1.50 g - Conservative ................. .................................................. ............ 0.30 g - Macadamia oil ................................ .................................... 1.00 g - Triethanolamine ............................................... ............................ 0.60 g - Cyclomethicone .................. .................................................. ....... 13.0 g - Dimethicone copolyol ...................................... ........................... 1.00 g - Phenyl Trimethicone .................. ................................................. 2.00 g - Ginkgo biloba extract ............................................ ................. 0.75 g - Seaweed extract .......................... .................................................. 1.00 g - Caffeine ............................................. ............................................ 2.00 g - Methylsilanol carboxymethyl theophylline alginate .................... 8. 00 g - Demineralised water qsp ..................... ........................................... 100 g Example 2: Gel emulsion H / E: - Carbopol 981 (marketed by Goodrich) .............................. 0.6 g - A ethyl alcohol ................................................ .......................... 15 g - volatile silicone oil ................. ............................................ 3 g
- Oil of purcellin .............................................. .......................... 7 g - Conservative .................... .................................................. .......... 0.3 g
- Anhydrous caffeine ............................................... ........................... 1 g
<Desc/Clms Page number 10><Desc / Clms Page number 10>
Parfum ......................................................................................... 0. 4 g
Extrait d algue ............................................................................. 2 g
Triéthanolamine........................................................................... 0. 2 g
Extrait de chrysanthellium indicum ............................................ g
Eau déminéralisée qsp ................................................................. 100 g Exemple 3 : Crème aux liposomes : - Huile de tournesol ....................................................................... 35 g - Alcool cétylique .......................................................................... 4 g - B-sitostérol.................................................................................. 4 g - Dicétyl phosphate ........................................................................ 0.5 g - Conservateur ............................................................................... 0.3 g - Parfum ......................................................................................... 0.6 g - Carbopol 981 (commercialisé par Goodrich) .............................. 0. 2 g - Triéthanolamine........................................................................... 0. 2 g
- Sphingosine .................................................................................0.05 g - Caféine ........................................................................................ g - Méthylsilanol carboxyméthyl théophylline alginate.................... 4 g
- Ginkgo biloba.............................................................................. 2 g - Eau déminéralisée qsp ................................................................ 100 g Les modes de réalisation ci-dessus peuvent avantageusement être utilisés sur les hanches afin d'en diminuer le volume. Le mode de réalisation ci-après peut être appliqué sur toutes zones dont le volume doit être réduit :
Emulsion EIH:
Protégin (commercialisépar Goldschmidt).................................. 19 g
Glycérine ..................................................................................... 3 g Perfume ................................................. ........................................ 0. 4 g
Seaweed extract ............................................... .............................. 2 g
Triethanolamine ................................................. .......................... 0. 2 g
Chrysanthellium indicum extract ............................................ g
Demineralized water qs ............................................... .................. 100 g Example 3: Cream with liposomes: - Sunflower oil ................... .................................................. .. 35 g - Cetyl alcohol ........................................... ............................... 4 g - B-sitosterol ............. .................................................. ................... 4 g - Diketyl phosphate .......................... .............................................. 0.5 g - Conservative .................................................. ............................. 0.3 g - Perfume ................. .................................................. ...................... 0.6 g - Carbopol 981 (marketed by Goodrich) .................. ............ 0. 2 g - Triethanolamine ................................ ........................................... 0. 2 g
- Sphingosine ................................................ ................................. 0.05 g - Caffeine ............. .................................................. ......................... g - Methylsilanol carboxymethyl theophylline alginate ................... 4 g
- Ginkgo biloba............................................... ............................... 2 g - Demineralized water qsp ............. .................................................. The above embodiments can advantageously be used on the hips in order to reduce their volume. The following embodiment can be applied to all areas whose volume must be reduced:
Emulsion EIH:
Protégin (marketed by Goldschmidt) .................................. 19 g
Glycerin ................................................. .................................... 3 g
<Desc/Clms Page number 11><Desc / Clms Page number 11>
Huile de vaseline ........................................................................ 8 g Sulfate de Mg .............................................................................. 0.5 g Parfum ......................................................................................... 0.8 g
Caféine.........................................................................................0.5 g
Extrait d'Enteromorpha compressa............................................. 2 g
Conservateur ............................................................................... 0.2 g
Eau déminéralisée qsp ................................................................ 100 g L'efficacité des exemples selon l'invention a été analysée par une étude sensorielle sur échelles analogiques pendant quatre semaines avec 114 sujets, sur l'amélioration de la forme et de l'esthétique générale du buste et des hanches. Vaseline oil ............................................... ......................... 8 g Mg Sulfate .................... .................................................. ........ 0.5 g Perfume ....................................... .................................................. 0.8 g
Caffeine................................................. ........................................ 0.5 g
Enteromorpha compressa extract ............................................. 2 g
Curator ................................................. .............................. 0.2 g
Demineralized water qs ............................................... 100 g The efficacy of the examples according to the invention was analyzed by a sensory study on analog scales for four weeks with 114 subjects, on the improvement of the shape and general aesthetics of the bust and hips.
Cette auto-évaluation fait appel à une technique de cotation couramment utilisée dans ce type d'In Use Test : la technique de cotation sur échelle analogique non structurée. This self-evaluation uses a scoring technique commonly used in this type of In Use Test: the unstructured analog scaling technique.
Cette méthode permet à chaque volontaire de se positionner, pour chacun des critères concernés, sur une échelle analogique continue, non structurée, matérialisée par une ligne de 10 cm, et comprise entre deux critères qualitatifs opposés. This method allows each volunteer to position themselves, for each of the criteria concerned, on a continuous analog scale, unstructured, materialized by a line of 10 cm, and between two opposite qualitative criteria.
Les 114 volontaires remplissent ces échelles analogiques avant le début de l'étude (TO) et de nouveau après quatre semaines d'utilisation du produit (T4s). The 114 volunteers complete these analog scales before the start of the study (TO) and again after four weeks of using the product (T4s).
Les produits sont distribués aux volontaires qui les appliquent une à deux fois par jours, pendant quatre semaines au niveau du buste pour le produit lipogénétique et au niveau des cuisses, du ventre et des hanches pour le produit lipolytique. The products are distributed to volunteers who apply them once or twice a day for four weeks at the bust for the lipogenetic product and at the thighs, belly and hips for the lipolytic product.
Une consigne leur est donnée : de bien se laver les mains entre l'application des deux produits. An instruction is given to them: to wash hands well between the application of the two products.
Les résultats sont exprimés par la moyenne des mesures en cm de la position du critère sur l'axe donné. The results are expressed as the average of the measurements in cm of the position of the criterion on the given axis.
<Desc/Clms Page number 12><Desc / Clms Page number 12>
Dans le cas présent, les sept critères suivants seront pris en compte : volume, fermeté, tenue, minceur, ventre, silhouette et cellulite. In this case, the following seven criteria will be taken into account: volume, firmness, resistance, thinness, belly, silhouette and cellulite.
Le test t de Student par paires a été utilisé lors de l'étude statistique. Student pair t test was used in the statistical study.
Test pour les Seins
Test for Breasts
<tb>
<tb> Items <SEP> Moyenne <SEP> TO <SEP> Moyenne <SEP> T4s <SEP> Evolution <SEP> % <SEP> Significativité
<tb> Augmentation <SEP> du <SEP> 3,683 <SEP> 2,584 <SEP> 4,255 <SEP> 2,245 <SEP> 15,53 <SEP> S <SEP>
<tb> volume <SEP> P <SEP> <0,001 <SEP>
<tb> Amélioration <SEP> de <SEP> 4,236 <SEP> 2,610 <SEP> 5,226 <SEP> 2,299 <SEP> 23,37 <SEP> S <SEP>
<tb> la <SEP> fermeté <SEP> P<0,001
<tb> Amélioration <SEP> de <SEP> 5,582 <SEP> 2,838 <SEP> 6,210 <SEP> 2,509 <SEP> 11,25 <SEP> S <SEP>
<tb> la <SEP> tenue <SEP> P <SEP> =0,002
<tb>
Test pour les Hanches
<Tb>
<tb> Items <SEP> Average <SEP> TO <SEP> Average <SEP> T4s <SEP> Evolution <SEP>% <SEP> Significance
<tb> Increased <SEP> by <SEP> 3,683 <SEP> 2,584 <SEP> 4,255 <SEP> 2,245 <SEP> 15.53 <SEP> S <SEP>
<tb> volume <SEP> P <SEP><0.001<SEP>
<tb> Improvement <SEP> of <SEP> 4,236 <SEP> 2,610 <SEP> 5,226 <SEP> 2,299 <SEP> 23,37 <SEP> S <SEP>
<tb> the <SEP> firmness <SEP> P <0.001
<tb> Improvement <SEP> of <SEP> 5,582 <SEP> 2,838 <SEP> 6,210 <SEP> 2,509 <SEP> 11,25 <SEP> S <SEP>
<tb><SEP> holding <SEP> P <SEP> = 0.002
<Tb>
Test for the Hips
<tb>
<tb> Items <SEP> Moyenne <SEP> TO <SEP> Moyenne <SEP> T4s <SEP> Evolution <SEP> % <SEP> Significativité
<tb> Amélioration <SEP> de <SEP> 3,621 <SEP> 2,431 <SEP> 4,675 <SEP> ~ <SEP> 2,373 <SEP> 28,61 <SEP> S
<tb> la <SEP> minceur <SEP> P <SEP> <0,001 <SEP>
<tb> Ventre <SEP> plus <SEP> plat <SEP> 4,136 <SEP> 2,795 <SEP> 4,707 <SEP> ~ <SEP> 2,250 <SEP> 13,80 <SEP> S
<tb> P <SEP> <0,001
<tb> Amélioration <SEP> de <SEP> 4,677 <SEP> 2,108 <SEP> 5,167 <SEP> ~ <SEP> 2,042 <SEP> 10,48 <SEP> S
<tb> la <SEP> silhouette <SEP> P <SEP> =0,002
<tb> Diminution <SEP> de <SEP> la <SEP> 6,132 <SEP> 2,648 <SEP> 5,200 <SEP> ~ <SEP> 2, <SEP> 314 <SEP> -15,20 <SEP> S
<tb> cellulite <SEP> P <SEP> #0,001
<tb>
S : Significatif. <Tb>
<tb> Items <SEP> Average <SEP> TO <SEP> Average <SEP> T4s <SEP> Evolution <SEP>% <SEP> Significance
<tb> Improvement <SEP> of <SEP> 3,621 <SEP> 2,431 <SEP> 4,675 <SEP> ~ <SEP> 2,373 <SEP> 28,61 <SEP> S
<tb> the <SEP> slimming <SEP> P <SEP><0,001<SEP>
<tb> Tummy <SEP> plus <SEP> flat <SEP> 4,136 <SEP> 2,795 <SEP> 4,707 <SEP> ~ <SEP> 2,250 <SE> 13,80 <SE> S
<tb> P <SEP><0.001
<tb> Improvement <SEP> of <SEP> 4,677 <SEP> 2,108 <SEP> 5,167 <SEP> ~ <SEP> 2,042 <SEP> 10,48 <SEP> S
<tb> the <SEP> silhouette <SEP> P <SEP> = 0.002
<tb> Decrease <SEP> of <SEP><SEP> 6,132 <SEP> 2,648 <SEP> 5,200 <SEP> ~ <SEP> 2, <SEP> 314 <SEP> -15,20 <SEP> S
<tb> cellulite <SEP> P <SEP># 0.001
<Tb>
S: Significant.
Le mode de réalisation de l'invention décrit ci-après est particulièrement préféré The embodiment of the invention described below is particularly preferred
<Desc/Clms Page number 13><Desc / Clms Page number 13>
pour le traitement des poitrines disproportionnées (produit lipolytique sur le gros sein et produit lipogénétique sur le petit sein). for the treatment of disproportionate breasts (lipolytic product on the large breast and lipogenetic product on the small breast).
Produit à appliquer sur le sein le plus volumineux
Emulsion E/H: - Protégin (commercialisé par Goldschmidt)................................. 19 g
- Glycérine ..................................................................................... 3 g - Huile de vaseline ............................................................................. 8 g - Sulfate de Mg .............................................................................. 0.5 g - Parfum ......................................................................................... 0.8 g - Caféine......................................................................................... 2 g - Extrait de Chrysanthellium indicum............................................ 3 g - Conservateur ............................................................................... 0.2 g - Eau déminéralisée qsp ..................................................................... 100 g Produit à appliquer sur le sein le plus petit :
Emulsion E/H : - Protégin (commercialisé par Goldschmidt)................................. 19 g - Glycérine ..................................................................................... 3 g - Huile de vaseline ........................................................................ 8 g - Sulfate de Mg 0. 5 g - Adénosine.................................................................................... 0. 02 g - Extrait de Ginseng ....................................................................... 4 g
- Rétinyl palmitate .........................................................................0.001 g - Conservateur ............................................................................... 0. 2 g - Eau déminéralisée qsp 100 g Product to be applied on the largest breast
W / O emulsion: - Protégin (marketed by Goldschmidt) ................................. 19 g
- Glycerin ................................................ ..................................... 3 g - Vaseline oil ....... .................................................. .................... 8 g - Mg Sulfate ........................ .................................................. .... 0.5 g - Perfume .......................................... ............................................... 0.8 g - Caffeine................................................. ........................................ 2 g - Chrysanthellium indicum extract ... ......................................... 3 g - Conservative ..... .................................................. ........................ 0.2 g - Demineralized water qsp .................... ................................................. 100 g Product to be applied to the smallest breast:
W / O emulsion: - Protégin (marketed by Goldschmidt) ................................. 19 g - Glycerine. .................................................. .................................. 3 g - Vaseline oil .......... .................................................. ............ 8 g - Mg Sulfate 0.5 g - Adenosine .......................... .................................................. ........ 0. 02 g - Ginseng extract .................................. ..................................... 4 g
- Retinyl palmitate ............................................... .......................... 0.001 g - Conservative .................... .................................................. ......... 0. 2 g - Demineralized water qs 100 g
<Desc/Clms Page number 14><Desc / Clms Page number 14>
Conseil d'utilisation : # Bien se laver les mains entre l'application des deux produits sur chacun les deux seins. Use: # Wash hands well between the application of the two products on each breast.
# Faire bien pénétrer les deux émulsions pour éviter tout mélange entre les produits. # Make the two emulsions penetrate well to avoid any mixing between the products.
Claims (2)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0212999A FR2845912B1 (en) | 2002-10-18 | 2002-10-18 | BINARY COSMETIC COMPOSITION FOR THE DEVELOPMENT OF THE FEMALE BUST AND THE IMPROVEMENT OF THE SILHOUETTE |
| EP03778395A EP1551365A1 (en) | 2002-10-18 | 2003-10-15 | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor |
| PCT/FR2003/003045 WO2004037221A1 (en) | 2002-10-18 | 2003-10-15 | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor |
| AU2003285404A AU2003285404A1 (en) | 2002-10-18 | 2003-10-15 | Method for cosmetic body treatment to enhance the silhouette and to develop the female bust, and double-acting cosmetic composition therefor |
| RU2005115101/14A RU2005115101A (en) | 2002-10-18 | 2003-10-15 | METHOD FOR COSMETIC BODY TREATMENT FOR THE PURPOSE OF IMPROVING THE FIGURES AND DEVELOPMENT OF FEMALE BUST AND TWO-COMPONENT COSMETIC COMPOSITION FOR ITS IMPLEMENTATION |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0212999A FR2845912B1 (en) | 2002-10-18 | 2002-10-18 | BINARY COSMETIC COMPOSITION FOR THE DEVELOPMENT OF THE FEMALE BUST AND THE IMPROVEMENT OF THE SILHOUETTE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2845912A1 true FR2845912A1 (en) | 2004-04-23 |
| FR2845912B1 FR2845912B1 (en) | 2006-06-30 |
Family
ID=32050516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0212999A Expired - Fee Related FR2845912B1 (en) | 2002-10-18 | 2002-10-18 | BINARY COSMETIC COMPOSITION FOR THE DEVELOPMENT OF THE FEMALE BUST AND THE IMPROVEMENT OF THE SILHOUETTE |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1551365A1 (en) |
| AU (1) | AU2003285404A1 (en) |
| FR (1) | FR2845912B1 (en) |
| RU (1) | RU2005115101A (en) |
| WO (1) | WO2004037221A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2879448A1 (en) * | 2004-12-17 | 2006-06-23 | Oreal | SLIMMING COMPOSITION COMPRISING A XANTHIC BASE, A COPOLYOL DIMETHICONE AND A POLYURETHANE POWDER |
| FR2950528A1 (en) * | 2009-09-29 | 2011-04-01 | Oreal | SLIMING COMPOSITION |
| US8409593B2 (en) | 2004-12-17 | 2013-04-02 | L'oreal | Methods for reducing tackiness associated with a xanthine compound |
| FR2988601A1 (en) * | 2012-04-02 | 2013-10-04 | Lucas Meyer Cosmetics | Use of hypoxia-inducible factor-1-alpha activator as an active agent in a topical cosmetic composition to enhance adipocyte mass and to combat or prevent aging including fine lines and wrinkles, preferably nasolabial fold |
| CN113260423A (en) * | 2018-10-26 | 2021-08-13 | 伊万·加拉宁 | Topical application composition and method for promoting optimal skin white adipose tissue composition in vivo |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2966040A1 (en) | 2010-10-19 | 2012-04-20 | Brigitte Gourlaouen | SLIMMING COMPOSITION AND / OR PREVENTING INFLAMMATORY PROCESSES |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992011838A1 (en) * | 1991-01-14 | 1992-07-23 | L'oreal | Utilization of a growth factor in a slimming composition |
| US5194259A (en) * | 1990-11-28 | 1993-03-16 | L'oreal | Slimming composition based on ginkgo biloba as an alpha-2-blocker |
| EP0685229A1 (en) * | 1995-06-01 | 1995-12-06 | Shiseido Company Limited | Skin cosmetic composition |
| EP1038518A1 (en) * | 1999-03-22 | 2000-09-27 | L'oreal | SLIMMING COMPOSITION containing a hydrosoluble film-forming polymer |
| US6261603B1 (en) * | 1999-05-11 | 2001-07-17 | Mcelwain Elizena A. | Skin cream |
| JP2001302494A (en) * | 2000-04-26 | 2001-10-31 | Johnson & Johnson Consumer France Sas | Composition including retinoid for skin care and caffeine |
-
2002
- 2002-10-18 FR FR0212999A patent/FR2845912B1/en not_active Expired - Fee Related
-
2003
- 2003-10-15 EP EP03778395A patent/EP1551365A1/en not_active Ceased
- 2003-10-15 RU RU2005115101/14A patent/RU2005115101A/en not_active Application Discontinuation
- 2003-10-15 WO PCT/FR2003/003045 patent/WO2004037221A1/en not_active Ceased
- 2003-10-15 AU AU2003285404A patent/AU2003285404A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194259A (en) * | 1990-11-28 | 1993-03-16 | L'oreal | Slimming composition based on ginkgo biloba as an alpha-2-blocker |
| WO1992011838A1 (en) * | 1991-01-14 | 1992-07-23 | L'oreal | Utilization of a growth factor in a slimming composition |
| EP0685229A1 (en) * | 1995-06-01 | 1995-12-06 | Shiseido Company Limited | Skin cosmetic composition |
| EP1038518A1 (en) * | 1999-03-22 | 2000-09-27 | L'oreal | SLIMMING COMPOSITION containing a hydrosoluble film-forming polymer |
| US6261603B1 (en) * | 1999-05-11 | 2001-07-17 | Mcelwain Elizena A. | Skin cream |
| JP2001302494A (en) * | 2000-04-26 | 2001-10-31 | Johnson & Johnson Consumer France Sas | Composition including retinoid for skin care and caffeine |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE WPI Derwent World Patents Index; AN 2002-158436, XP002242350, "Reducing lipidemia involves administering composition comprising retinoid and caffeine to skin" * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2879448A1 (en) * | 2004-12-17 | 2006-06-23 | Oreal | SLIMMING COMPOSITION COMPRISING A XANTHIC BASE, A COPOLYOL DIMETHICONE AND A POLYURETHANE POWDER |
| EP1676606A1 (en) * | 2004-12-17 | 2006-07-05 | L'oreal | Slimming composition comprising a xanthin base, a dimethicone copolyol and a polyurethane powder |
| US8409593B2 (en) | 2004-12-17 | 2013-04-02 | L'oreal | Methods for reducing tackiness associated with a xanthine compound |
| FR2950528A1 (en) * | 2009-09-29 | 2011-04-01 | Oreal | SLIMING COMPOSITION |
| EP2305206A1 (en) * | 2009-09-29 | 2011-04-06 | L'Oréal | Slimming composition |
| FR2988601A1 (en) * | 2012-04-02 | 2013-10-04 | Lucas Meyer Cosmetics | Use of hypoxia-inducible factor-1-alpha activator as an active agent in a topical cosmetic composition to enhance adipocyte mass and to combat or prevent aging including fine lines and wrinkles, preferably nasolabial fold |
| CN113260423A (en) * | 2018-10-26 | 2021-08-13 | 伊万·加拉宁 | Topical application composition and method for promoting optimal skin white adipose tissue composition in vivo |
| EP3870311A4 (en) * | 2018-10-26 | 2022-12-28 | Galanin, Ivan | TOPICAL COMPOSITIONS AND METHODS FOR PROMOTING OPTIMAL COMPOSITION OF DERMAL WHITE Adipose Tissue IN VIVO |
| US12226517B2 (en) | 2018-10-26 | 2025-02-18 | Ivan GALANIN | Topical compositions and methods to promote optimal dermal white adipose tissue composition in vivo |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1551365A1 (en) | 2005-07-13 |
| RU2005115101A (en) | 2005-10-27 |
| AU2003285404A1 (en) | 2004-05-13 |
| WO2004037221A1 (en) | 2004-05-06 |
| FR2845912B1 (en) | 2006-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2056322C (en) | Ginkgo biloba acting as alpha-2-blocker slimming compound | |
| JP4280341B2 (en) | Cosmetic composition containing moisturizing plant extract | |
| BE1009622A3 (en) | Hygiene and cosmetic preparations for prevention and treatment of skin diseases and a method for preparing. | |
| JPH06506668A (en) | Use of growth factors in slimming compositions | |
| CA2136706C (en) | Process for controlling adiposity and compositions for use therein | |
| FR2880802A1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT | |
| FR2695318A1 (en) | Topical composition intended for the rejuvenation of the skin. | |
| CA2327003A1 (en) | Process for making phytocosmetic and phytodermatological external skin care products | |
| WO2010112084A1 (en) | Topical cosmetic compositions for treating or preventing cellulite | |
| JPH02504638A (en) | Botanical active substance preparations for use in cosmetics | |
| FR2845912A1 (en) | Cosmetic method for developing the bust and improving the figure, comprises separate lipolytic and lipogenic components | |
| KR100761660B1 (en) | Hair growth promoting composition | |
| RU2180214C1 (en) | Cream scrub | |
| FR2880278A1 (en) | USE OF OIL AND PROTEINS EXTRACTED FROM PLUKENETIA VOLUBILIS LINNEO SEEDS IN COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL PREPARATIONS | |
| FR2729079A1 (en) | Cosmetic compsn contg synthetic ceramide and protease | |
| JPH11315007A (en) | Collagen productive promoter and preparation for external use for skin | |
| EP1684774B1 (en) | Stimulation of hair growth by isoginkgetin | |
| CN108403588A (en) | Natural Plant & Animal Moisturizer | |
| JP2004149424A (en) | Cosmetic and method for improving humectant function of cosmetic | |
| JP2005289999A (en) | Cosmetic composition comprising jujube extract and walnut extract | |
| JP3382149B2 (en) | External preparation for head | |
| RU2120278C1 (en) | Agent for strengthening and growing hair | |
| FR2723314A1 (en) | Skin compsns. contg. Centaurium and Siegesbeckia orientalis extracts | |
| JP4577596B2 (en) | Hair restorer or hair growth agent and method of use thereof | |
| FR3011742A1 (en) | NOVEL ACTIVE TO HOMOGENIZE LIP VERMILLON AND COSMETIC COMPOSITIONS COMPRISING SAME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |
Effective date: 20150630 |